Investing.com – France stocks were higher after the close on Tuesday, as gains in the Foods & Drugs, Gas & Water and General Financial sectors led shares higher. At the close in...
Investing.com – France stocks were higher after the close on Thursday, as gains in the Foods & Drugs, Gas & Water and General Financial sectors led shares higher. At the close in...
The Wall Street suffered one of its worst weeks since the financial crisis with all the three major indices declining more than 5% each, marking their worst loss in more than two...
Further VIPES responder analyses at EAACIAdditional data from DBV Technologies (PARIS:DBV)’s Phase IIb VIPES trial have been presented at EAACI. A further post hoc analysis...
Key opinion leaders reinforce patch potentialDBV Technologies' (PARIS:DBV) investor event underlined the medical need for Viaskin Peanut, with key opinion leaders (KOLs)...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Sell | Sell | Strong Sell | Strong Sell | Neutral |
| Summary | Sell | Sell | Strong Sell | Strong Sell | Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 351.24 | 353.77 | 347.70 | -0.71 | -0.20% | 12.41M | NASDAQ | |||
| 2,712.60 | 2,714.60 | 2,666.40 | +15.5 | +0.58% | 1.04M | NASDAQ | |||
| 103.06 | 103.20 | 98.11 | +2.46 | +2.45% | 14.44M | NYSE | |||
| 197.38 | 197.44 | 192.00 | -2.71 | -1.35% | 20.12M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 21.72 | 21.77 | 21.53 | +0.15 | +0.70% | 10.74M | NYSE | |||
| 198.15 | 202.22 | 192.20 | +0.65 | +0.33% | 30.18M | NASDAQ | |||
| 19.74 | 19.84 | 18.99 | +0.48 | +2.49% | 7.61M | NYSE | |||
| 6.52 | 6.556 | 6.45 | +0.020 | +0.31% | 6.80M | NYSE | |||
| 64.03 | 64.65 | 63.95 | -0.06 | -0.09% | 612.48K | NYSE | |||
| 1.08 | 1.10 | 1.06 | -0.0100 | -0.92% | 3.09M | NYSE | |||
| 13.64 | 13.68 | 13.42 | +0.10 | +0.74% | 2.37M | NYSE | |||
| 0.61 | 0.00 | 0.00 | +0.0058 | +0.96% | 676.00K | NYSE | |||
| 230.18 | 235.69 | 226.91 | -5.22 | -2.22% | 2.85M | NASDAQ | |||
| 79.84 | 79.93 | 78.96 | +0.32 | +0.40% | 583.43K | NYSE |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow’s milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen’s egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn’s disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.
